The University of Oxford today announced the R21/Matrix-MTM malaria vaccine had been licensed for use in the Republic of Ghana by the local Food and Drugs Authority.
The R21/Matrix-M™ malaria vaccine was developed by the University of Oxford, leveraging an adjuvant technology from Novavax, and manufactured and scaled up by Serum Institute of India Pvt Ltd (SIIPL).
SIIPL has already established manufacturing capacities of more than 200 million vaccine doses annually.
Read More
